FERTIGYN 10000 is a high-potency injectable formulation of human chorionic gonadotropin (hCG) with a strength of 10,000 international units (IU) per vial. hCG is a hormone naturally produced during pregnancy and structurally similar to luteinizing hormone (LH). In medical practice, hCG injections are used to treat infertility in women by triggering the final maturation and release of an egg (ovulation) after follicle development, and to support luteal phase hormonal levels. In men and adolescent boys, hCG is used to stimulate testosterone production and to treat conditions such as hypogonadotropic hypogonadism or undescended testes (cryptorchidism).
Due to its high dose, FERTIGYN 10000 is typically prescribed when lower doses are insufficient or when robust hormonal stimulation is required. The injection should only be administered by a healthcare professional in a clinic or under supervised conditions. Dosing schedules vary depending on the indication: for female infertility, a single injection is commonly given following follicular stimulation; for male hypogonadism, injections may be administered multiple times per week over several weeks. Patients must strictly adhere to the treatment plan outlined by their fertility specialist or endocrinologist.
Possible side effects of hCG therapy include injection site reactions (pain, swelling), headache, fatigue, irritability or mood changes. In women undergoing fertility treatment, there is a risk of ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, bloating and fluid retention. Use of hCG may also increase the likelihood of multiple pregnancies. Men may experience water retention, acne, mood changes or, rarely, gynecomastia. Individuals with hormone-sensitive cancers, uncontrolled thyroid or adrenal disorders, or allergic reactions to hCG should not use FERTIGYN 10000.
When administered responsibly under medical supervision, FERTIGYN 10000 can be a valuable tool in assisted reproductive technologies and hormone replacement therapy.
Due to its high dose, FERTIGYN 10000 is typically prescribed when lower doses are insufficient or when robust hormonal stimulation is required. The injection should only be administered by a healthcare professional in a clinic or under supervised conditions. Dosing schedules vary depending on the indication: for female infertility, a single injection is commonly given following follicular stimulation; for male hypogonadism, injections may be administered multiple times per week over several weeks. Patients must strictly adhere to the treatment plan outlined by their fertility specialist or endocrinologist.
Possible side effects of hCG therapy include injection site reactions (pain, swelling), headache, fatigue, irritability or mood changes. In women undergoing fertility treatment, there is a risk of ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, bloating and fluid retention. Use of hCG may also increase the likelihood of multiple pregnancies. Men may experience water retention, acne, mood changes or, rarely, gynecomastia. Individuals with hormone-sensitive cancers, uncontrolled thyroid or adrenal disorders, or allergic reactions to hCG should not use FERTIGYN 10000.
When administered responsibly under medical supervision, FERTIGYN 10000 can be a valuable tool in assisted reproductive technologies and hormone replacement therapy.
0